In the lung carcinoma syngeneic model, we confirmed that RORγt agonist treatment increased intratumoral CD8+ T cells and MoDCs through the promotion of CXCL10 as well as promotion of Type 17 T cell migration via upregulation of CCL20 and CCR6 expression. Here, CD8A is linked to lung carcinoma.